Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Conte

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis and Related Disorders|October 26, 2022
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Irene Schiavetti, Roberto Bergamaschi, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2024
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancyDoriana Landi, Silvia Bartolomeo, Francesca Bovis, et al.
Journal of Neurology|March 10, 2026
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMSTommaso Guerra, Giuseppe Lucisano, Maria A Rocca, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Neurology|December 21, 2022
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple SclerosisGiacomo Boffa, Alessio Signori, Luca Massacesi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Multiple Sclerosis and Related Disorders|October 26, 2022
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Irene Schiavetti, Roberto Bergamaschi, et al.
Journal of Neurology|June 28, 2021
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara G Chisari, Giancarlo Comi, Massimo Filippi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 12, 2024
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancyDoriana Landi, Silvia Bartolomeo, Francesca Bovis, et al.
Journal of Neurology|March 10, 2026
HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMSTommaso Guerra, Giuseppe Lucisano, Maria A Rocca, et al.
Pageof 25